PD-1单抗联合化疗与化疗治疗III-IV期SMARCA4缺失型非小细胞肺癌的疗效评估及预后分析

Background and objective The SMARCA4 mutation has been shown to account for at least 10% of non-small cell lung cancer (NSCLC). In the present, conventional radiotherapy and targeted therapy are difficult to improve outcomes due to the highly aggressive and refractory nature of SMARCA4-deficient NSC...

Descripción completa

Detalles Bibliográficos
Autores principales: WANG, Xinjuan, TU, Meng, JIA, Hongxia, LIU, Hongping, WANG, Yan, WANG, Yibo, JIANG, Nan, LU, Chunya, ZHANG, Guojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial board of Chinese Journal of Lung Cancer 2023
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600746/
https://www.ncbi.nlm.nih.gov/pubmed/37985152
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.26

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600746/
https://www.ncbi.nlm.nih.gov/pubmed/37985152
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.26

Ejemplares similares